ArticleAnnals of clinical and translational neurology2024

Ocrelizumab alters the circulating metabolome in people with relapsing-remitting multiple sclerosis.

Fatemeh Siavoshi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.